Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Monday that the first patient has been dosed in the global multicentre Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 transpacific antibody, CS2009, with no infusion reactions or other adverse events observed.

This trial aims to evaluate the clinical potential of CS2009 in a wide range of advanced solid tumours including non-small cell lung cancer, hepatocellular carcinoma, gastric adenocarcinoma, endometrial cancer, ovarian cancer, renal cell carcinoma and cervical cancer, in efforts to advance the development of innovative tumour immunotherapies.

CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets -- PD-1, VEGFA and CTLA-4 -- and exerts multidimensional anti-tumour effects through synergistic actions.

According to CStone, in preclinical studies CS2009 demonstrated superior anti-tumour activity compared to potential competitors. By combining CTLA-4 inhibition with PD-1 and VEGFA blockade, CS2009 may further enhance benefits for patients with low or negative PD-L1 expression, who respond poorly to PD-(L)1 therapies. This well positions CS2009 as a next-generation, first- or best-in-class immunotherapy backbone, with the potential to replace current anti-PD-(L)1-based therapies.